Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Docetaxel-Oxaliplatin-Capecitabine (DOX) with dose adjustment in advanced gastric adenocarcinoma and suboptimal performance status
2008-001825-32Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective response rate. Started May 2008; status: completed.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2008-001825-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001825-32.